Selskabets formål er at udvikle, kommercialisere og sælge et automatisk injektionssystem til radioaktivt vand.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 1.8 mio. | -35.1 mio. | 337.1 mio. | 302.6 mio. | 31 | |
CVR: 36497661
Secondary names: aQuant A/S, MedTrace A/S
Previous names: LSW MEDICAL IVS, Medtrace ApS, MedTrace A/S
Compared to 477 companies in Udlejning og leasing af andet materiel, udstyr og andre materielle aktiver til events
Comparison is based on industry median values
Arbejdsmarkedets Tillægspension registered with 33% ownership
MedTravest IV ApS registered with 15% ownership
Ellen Rietmann Ahl joined the board
Robert Karl Schier left the board
Charlotte Vindfeldt joined the board
Peter Juul Kristensen joined as ADM. DIR.
Peter Juul Kristensen left the board
The financial health of MedTrace Pharma A/S shows significant challenges, with consistent losses over the past five years. Revenue peaked at 2,645,338 DKK in 2023 but has since declined to 1,759,371 DKK in 2025, while cumulative losses have reached -35,131,112 DKK in the latest year. Despite these losses, the company maintains a strong equity position of 302,613,643 DKK, indicating resilience and potential for recovery. However, the declining revenue trend and persistent negative profit margins raise concerns about its operational sustainability within the event equipment leasing industry.
AI-generated summary
Companies in the same industry and area
companydata.dk